Precisis GmbH (Precisis) develops innovative medical device products in the field of neurostimulation for the treatment of functional cerebral diseases. The company develops EASEE system, an individual-focused transcranial brain stimulation method that involves subcutaneous electrodes placed outside the cranium for stabilizing diseased brain areas in the treatment of seizure disorders, epilepsy, cognitive dysfunction, and rehabilitation after stroke. EASEE stimulation system is an implantable medical device exhibiting epileptic activity with anatomical precision in a minimally invasive procedure. Precisis is headquartered in Heidelberg, Baden-Wurttemberg, Germany.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Precisis GmbH
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Precisis GmbH Company Overview
- Precisis GmbH Company Snapshot
- Precisis GmbH Pipeline Products and Ongoing Clinical Trials Overview
- Precisis GmbH - Pipeline Analysis Overview
- Precisis GmbH - Key Facts
- Precisis GmbH - Major Products and Services
- Precisis GmbH Pipeline Products by Development Stage
- Precisis GmbH Ongoing Clinical Trials by Trial Status
- Precisis GmbH Pipeline Products Overview
- EASEE Next Generation System
- EASEE Next Generation System Product Overview
- EASEE System - Epilepsy
- EASEE System - Epilepsy Product Overview
- EASEE System - Epilepsy Clinical Trial
- EASEE System - Major Depressive Disorder
- EASEE System - Major Depressive Disorder Product Overview
- EASEE System - Stroke
- EASEE System - Stroke Product Overview
- Precisis GmbH - Key Competitors
- Precisis GmbH - Key Employees
- Precisis GmbH - Locations And Subsidiaries
- Head Office
- Recent Developments
- Precisis GmbH, Recent Developments
- Oct 16, 2023: EASEE: The Innovation in Epilepsy Treatment - The Groundbreaking Implant in the Spotlight of Medtech Outlook
- Apr 04, 2023: Newly-Published Data Demonstrates Safety and Efficacy of World’s First Minimally Invasive Brain Pacemaker
- Jan 06, 2023: First Prize of the Esteemed American Epilepsy Foundation Shark Tank Goes to Precisis
- Sep 23, 2022: Minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately
- Apr 29, 2022: Clinical Studies Demonstrate that Patients with Focal Epilepsies Benefit from the Technologically Innovative Therapy EASEE
- Feb 21, 2022: Minimally invasive epilepsy treatment EASEE receives FDA breakthrough device designation
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Precisis GmbH Pipeline Products and Ongoing Clinical Trials Overview
- Precisis GmbH Pipeline Products by Equipment Type
- Precisis GmbH Pipeline Products by Indication
- Precisis GmbH Ongoing Clinical Trials by Trial Status
- Precisis GmbH, Key Facts
- Precisis GmbH, Major Products and Services
- Precisis GmbH Number of Pipeline Products by Development Stage
- Precisis GmbH Pipeline Products Summary by Development Stage
- Precisis GmbH Ongoing Clinical Trials by Trial Status
- Precisis GmbH Ongoing Clinical Trials Summary
- EASEE Next Generation System - Product Status
- EASEE Next Generation System - Product Description
- EASEE System - Epilepsy - Product Status
- EASEE System - Epilepsy - Product Description
- EASEE System - Epilepsy - Easee System - Long-Term Registry on Epilepsy Evolution In Subjects Treated with Transcranial Focal Cortex Stimulation
- EASEE System - Epilepsy - EASEE4YOU - A Clinical Investigation of the Safety and Efficacy of Transcranial Focal Cortex Stimulation with the EASEE System for the Treatment of Medically Refractory Focal Epilepsy in Young Patients, Aged 12 to 17 Years
- EASEE System - Major Depressive Disorder - Product Status
- EASEE System - Major Depressive Disorder - Product Description
- EASEE System - Stroke - Product Status
- EASEE System - Stroke - Product Description
- Precisis GmbH, Key Employees
- Glossary
- Precisis GmbH Pipeline Products by Equipment Type
- Precisis GmbH Pipeline Products by Development Stage
- Precisis GmbH Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BrainLAB AG
- Elekta GmbH
- EIT Health eV
